BioLineRx to Report First Quarter 2024 Results on May 28, 2024

Rhea-AI Summary

BioLineRx (NASDAQ: BLRX), a biopharmaceutical company focused on oncology and rare diseases, will release its unaudited first-quarter financial results for 2024 on May 28, 2024, before U.S. market hours. A conference call will be held at 8:30 a.m. EDT, hosted by CEO Philip Serlin. Access to the call is available via several international dial-ins, with a live webcast and replay accessible on the company's website. Dial-in replays will be available until May 30, 2024.

Positive

• Company is releasing financial results early, before U.S. markets open, which may indicate confidence.
• Conference call with CEO provides direct communication with investors, enhancing transparency.

Negative

• Results are unaudited, which may raise concerns about their accuracy among investors.
• No specific guidance or preliminary earnings figures mentioned in the announcement.

Management to Hold Conference Call at 8:30 a.m. EDT

TEL AVIV, Israel, May 22, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2024 on Tuesday, May 28, 2024, before the U.S. markets open.

The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until May 30, 2024; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.  and events.

CONTACTS:

United States
John Lacey
BioLineRx
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-first-quarter-2024-results-on-may-28-2024-302151919.html

SOURCE BioLineRx

FAQ

When will BioLineRx release its Q1 2024 financial results?

BioLineRx will release its Q1 2024 financial results on May 28, 2024.

What time is the BioLineRx conference call for Q1 2024 results?

The BioLineRx conference call for Q1 2024 results is at 8:30 a.m. EDT.

How can I access the BioLineRx Q1 2024 earnings call?

You can access the BioLineRx Q1 2024 earnings call by dialing +1-888-281-1167 in the U.S. or +972-3-918-0685 internationally, or via the live webcast on the company's website.

What is the NASDAQ ticker symbol for BioLineRx?

The NASDAQ ticker symbol for BioLineRx is BLRX.

How long will the replay of the BioLineRx Q1 2024 call be available?

The replay of the BioLineRx Q1 2024 call will be available until May 30, 2024.